Clinical Trials Logo

Ulcer clinical trials

View clinical trials related to Ulcer.

Filter by:

NCT ID: NCT02578004 Completed - Pressure Ulcers Clinical Trials

Risk Factors for Pressure Ulcers

Start date: January 2013
Phase: N/A
Study type: Observational

Development of pressure ulcer (PU) is complex and multifactorial. The association of a constituted PU and of clinical / biological major elements is demonstrated and justifies. Prevention of PU is an important health priority, one that requires clear identification of risk factors.

NCT ID: NCT02569333 Completed - Clinical trials for Inflammatory Bowel Diseases

Patient Centered Algorithms to Optimize the Inpatient Experience and Treatment of Ulcerative Colitis

PATIENT-UC
Start date: January 2016
Phase: N/A
Study type: Interventional

Hospitalized patients with ulcerative colitis (UC) are at increased risk for a variety of complications such as infections, venous thrombosis, and surgery. The literature has revealed significant variation in the quality of care to hospitalized UC patients. As a result, guidelines for the management of these patients have been developed. However, the update of guidelines are variable. Admission to hospital can also have significant impact on quality of life due to interruptions in life commitments and lost sense of control of disease. Maintaining a sense of self-control of disease and active participation in care has been shown to be valuable among individuals with chronic diseases. The investigators propose the development of a multi-site, patient centred initiative aimed at improving clinical and patient-centered outcomes through an educational iPad based tool for patients admitted to hospital with ulcerative colitis.

NCT ID: NCT02565797 Completed - Pressure Ulcer Clinical Trials

Comparative Prevention-effectiveness Trial of DabirAIR Overlay System

Start date: November 2015
Phase: N/A
Study type: Interventional

Henry Ford Health System will evaluate the DabirAIR overlay system (DOS) for its effectiveness in preventing hospital acquired pressure ulcer (HAPU) in the peri-operative setting. The primary objective of the study is to compare the prevention-effectiveness (incidence rate of HAPU) between DOS (treatment group) vs facility specific standard of care pressure-relieving device(s) (control group) peri-operatively to discharge.

NCT ID: NCT02559713 Completed - Crohn's Disease Clinical Trials

Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease

Start date: November 29, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the concentration of vedolizumab in breast milk of lactating women with active ulcerative colitis (UC) or Crohn's disease (CD) who are receiving vedolizumab therapeutically.

NCT ID: NCT02551744 Completed - Peptic Ulcer Clinical Trials

Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers

Start date: July 2012
Phase: N/A
Study type: Interventional

Whether pantoprazole versus famotidine for the prevention of recurrent peptic ulcers in thienopyridine users remains unclear.

NCT ID: NCT02550418 Completed - Colitis, Ulcerative Clinical Trials

Budesonide 9 mg Capsules in Active UC

TOPICAL-1
Start date: October 2015
Phase: Phase 2
Study type: Interventional

The purpose of the trial is to evaluate the efficacy of an 8 week treatment with once-daily 9 mg budesonide in patients with active ulcerative colitis

NCT ID: NCT02537210 Completed - Colitis, Ulcerative Clinical Trials

Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis

Start date: September 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether aminosalicylic acid (ASA) can be safely withdrawn in patients with long-standing clinical inactive UC.

NCT ID: NCT02536989 Completed - Hemorrhage Clinical Trials

Different Dose of Intravenous Omeprazole to Treat Bleeding Ulcer With Adherent Clot

Start date: March 2009
Phase: Phase 4
Study type: Interventional

The investigators will include those patients with adherent clot on gastric or duodenal ulcers after endoscopic confirmation After receiving well explanation and giving written consent, they are enrolled and will be allocated to 2 groups randomly. Those in the first group will receive intravenous omeprazole 40 mg stat and then 40 mg q12h. Those in the second group will receive intravenous omeprazole 80 mg stat and then 8mg/hr infusion. The patients in both groups will receive intravenous omeprazole for 3 days and then oral esomeprazole qd for further treatment of peptic ulcer. The investigators define rebleeding during admission and within 30 days as primary end points and define surgical intervention for ulcer bleeding, transfusion amount and hospitalization days after allocation as secondary end points.

NCT ID: NCT02536404 Completed - Ulcerative Colitis Clinical Trials

Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis

Start date: January 25, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.

NCT ID: NCT02535481 Completed - Wounds and Injuries Clinical Trials

Epidermal Grafting in Wound Healing

EPIGRAAFT
Start date: October 2015
Phase: N/A
Study type: Interventional

Split thickness skin grafting is the normal standard of care for wound closure. However, this is an invasive procedure and associated with pain also there can be additional donor site morbidity. Epidermal grafting is an emerging clinical alternative that is gaining clinical practise. Epidermal grafting (EG) is an alternative method of autologous skin grafting that 'harvests' a finer layer of skin than traditional Split thickness skin grafting (SSG). This potentially results in less pain and reduced donor site morbidity but only delivers several cell layers to the wound so may be less effective at healing a wound. It is not known if EG is an effective alternative to SSG. Further the mechanism to achieve wound healing may be different. EG promotes wound healing by expressing growth factors that accelerates wound healing and encourages keratinocyte migration. Whereas SSG is a transplant of several skin layers that integrated to the existing wound bed as a formal skin covering. The investigators wish to compare these two clinical practises; epidermal grafting and split thickness skin grafting in wound healing. Further to undertake a translational study to investigate the mechanism by which each technique achieves wound healing.